Home > Research > Publications & Outputs > Using biomarkers to allocate patients in a resp...

Links

Text available via DOI:

View graph of relations

Using biomarkers to allocate patients in a response-adaptive clinical trial

Research output: Contribution to Journal/MagazineJournal articlepeer-review

E-pub ahead of print

Standard

Using biomarkers to allocate patients in a response-adaptive clinical trial. / Jackson, H.; Bowen, Sarah; Jaki, T.

In: Communications in Statistics: Simulation and Computation, 25.11.2021.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Author

Jackson, H. ; Bowen, Sarah ; Jaki, T. / Using biomarkers to allocate patients in a response-adaptive clinical trial. In: Communications in Statistics: Simulation and Computation. 2021.

Bibtex

@article{87e5544b8cea4407a9c313a191c24196,
title = "Using biomarkers to allocate patients in a response-adaptive clinical trial",
abstract = "In this paper, we discuss a response adaptive randomization method, and why it should be used in clinical trials for rare diseases compared to a randomized controlled trial with equal fixed randomization. The developed method uses a patient{\textquoteright}s biomarkers to alter the allocation probability to each treatment, in order to emphasize the benefit to the trial population. The method starts with an initial burn-in period of a small number of patients, who with equal probability, are allocated to each treatment. We then use a regression method to predict the best outcome of the next patient, using their biomarkers and the information from the previous patients. This estimated best treatment is assigned to the next patient with high probability. A completed clinical trial for the effect of catumaxomab on the survival of cancer patients is used as an example to demonstrate the use of the method and the differences to a controlled trial with equal allocation. Different regression procedures are investigated and compared to a randomized controlled trial, using efficacy and ethical measures. ",
keywords = "Biomarker, Patient benefit, Personalized medicine, Response adaptive clinical trial",
author = "H. Jackson and Sarah Bowen and T. Jaki",
year = "2021",
month = nov,
day = "25",
doi = "10.1080/03610918.2021.2004420",
language = "English",
journal = "Communications in Statistics – Simulation and Computation",
issn = "0361-0918",
publisher = "Taylor and Francis Ltd.",

}

RIS

TY - JOUR

T1 - Using biomarkers to allocate patients in a response-adaptive clinical trial

AU - Jackson, H.

AU - Bowen, Sarah

AU - Jaki, T.

PY - 2021/11/25

Y1 - 2021/11/25

N2 - In this paper, we discuss a response adaptive randomization method, and why it should be used in clinical trials for rare diseases compared to a randomized controlled trial with equal fixed randomization. The developed method uses a patient’s biomarkers to alter the allocation probability to each treatment, in order to emphasize the benefit to the trial population. The method starts with an initial burn-in period of a small number of patients, who with equal probability, are allocated to each treatment. We then use a regression method to predict the best outcome of the next patient, using their biomarkers and the information from the previous patients. This estimated best treatment is assigned to the next patient with high probability. A completed clinical trial for the effect of catumaxomab on the survival of cancer patients is used as an example to demonstrate the use of the method and the differences to a controlled trial with equal allocation. Different regression procedures are investigated and compared to a randomized controlled trial, using efficacy and ethical measures.

AB - In this paper, we discuss a response adaptive randomization method, and why it should be used in clinical trials for rare diseases compared to a randomized controlled trial with equal fixed randomization. The developed method uses a patient’s biomarkers to alter the allocation probability to each treatment, in order to emphasize the benefit to the trial population. The method starts with an initial burn-in period of a small number of patients, who with equal probability, are allocated to each treatment. We then use a regression method to predict the best outcome of the next patient, using their biomarkers and the information from the previous patients. This estimated best treatment is assigned to the next patient with high probability. A completed clinical trial for the effect of catumaxomab on the survival of cancer patients is used as an example to demonstrate the use of the method and the differences to a controlled trial with equal allocation. Different regression procedures are investigated and compared to a randomized controlled trial, using efficacy and ethical measures.

KW - Biomarker

KW - Patient benefit

KW - Personalized medicine

KW - Response adaptive clinical trial

U2 - 10.1080/03610918.2021.2004420

DO - 10.1080/03610918.2021.2004420

M3 - Journal article

JO - Communications in Statistics – Simulation and Computation

JF - Communications in Statistics – Simulation and Computation

SN - 0361-0918

ER -